Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta-analysis of randomized control trials

Yomna Ali Abdelghafar1 | Yossef Hassan AbdelQadir1 | Karam R. Motawa1 | Sara Amr Nasr1 | Hoda Aly Mohamed Omran1 | Mohamed Mohamed Belal1 | Mohamed Mahdy Elhashash1 | Ahmed Alaa AbdelAzim2 | Jaffer Shah3

1Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Faculty of Medicine, Beni Suef University, Beni Suef, Egypt
3New York State Department of Health, New York, NY, USA

Correspondence
Jaffer Shah, New York State Department of Health, New York, NY, USA.
Email: jaffer.shah@kateb.edu.af

Abstract

Background and Aims: Fecal microbiota transfer (FMT) is a potential treatment for irritable bowel syndrome (IBS). Several randomized trials have tested FMT effects using different routes of administration, doses, and sample sizes. We aim to assess the overall efficacy of FMT for IBS patients and the safety of the intervention.

Methods: We systematically searched four databases for randomized control trials that studied the efficacy and safety of FMT in IBS patients.

Results: We included 8 randomized trials (472 patients) that compared FMT with placebo in IBS patients. Pooled results showed no statistically significant difference between FMT and control groups in the overall change in IBS symptom severity (IBS-SSS) at 1 month ($p = 0.94$), 3/4 months ($p = 0.82$), and at the end of trials ($p = 0.67$). No significant difference in the total number of respondents between the FMT and control groups (risk ratios $= 1.84$, [95% confidence interval (CI) $= 0.82–2.65$], $p = 0.19$). Although the oral route of administration showed a significant difference in the number of respondents ($p = 0.004$), there was no statistically significant difference in the IBS-SSS when subgrouping the oral route of administration (mean difference $= 47.57$, [95% CI $= −8.74–103.87$], $p = 0.10$).

Conclusion: FMT is not an effective treatment to relieve all the symptoms of IBS. Even in the groups that showed relatively significant improvement after FMT, the effect was proven to wear off over time and the re-administration carries a low success rate. Future research should consider different bacterial-based interventions such as probiotics or specific antibiotics.

Keywords
constipation, fecal microbiota transfer, irritable bowel syndrome, quality of life

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
1 | INTRODUCTION

Irritable bowel syndrome (IBS) is a chronic multifactorial functional gastrointestinal disorder, that develops in the middle or lower parts of the gastrointestinal tract (GIT).\textsuperscript{1,2} It is a symptom-based disorder that is currently clinically diagnosed by Rome criteria.\textsuperscript{3,4}

Rome III and Rome IV criteria resulted in more specific diagnosis and lower prevalence rates of IBS.\textsuperscript{5,6} Rome IV is the last update that was released in May 2016, one of the main modifications to the Rome III criteria is that discomfort is no longer accounted for and abdominal pain is now mandatory for diagnosis, also symptom frequency to be at least once per week.\textsuperscript{6} IBS presents with many symptoms that include abdominal distention, bloating, and pain, as well as altered bowel habits.\textsuperscript{3,7} According to the symptom presentation, IBS is classified into three subtypes; IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed bowel pattern (IBS-M).\textsuperscript{8}

Most recent studies suggest that the worldwide prevalence of IBS currently ranges between 4% and 10%, with the lowest prevalence rates in Singapore, and the highest prevalence rates in Egypt. It is also shown that the prevalence of IBS is higher in women than in men. Regarding age, studies have shown that IBS is more common among adults, and as age increases the prevalence of IBS decreases.\textsuperscript{5,6,9,10} IBS patients are more likely to suffer from depression and lower quality of life (QOL), the incidence of depression co-occurrence in IBS patients is estimated to be between 44% and 84%.\textsuperscript{11}

Although the exact etiology of IBS is still unknown, studies suggest that multiple factors including inflammatory agents, visceral hypersensitivity, genetic factors, disorders in gut–brain interaction, and psychosocial stress, all contribute to the pathogenesis of IBS.\textsuperscript{7–9} Consequently, there is an imbalance in the gut microbiota, which is known as dysbiosis, which results in a disturbance of the integrity of the mucosal epithelium as well as GIT motility.\textsuperscript{12,13}

Recent research studies on gut microbiome-focused treatment for IBS explore the manipulation of gut microbiota by prebiotics, probiotics, antibiotics, dietary changes, and fecal microbiota transfer (FMT).\textsuperscript{14} In this review, we focus on FMT. FMT is a novel treatment to restore the balance of gut microbiota through the transfer of fecal microbiota of a healthy donor into the patient's GIT via either oral capsules, nasojejunal, or endoscope.\textsuperscript{15} It has proved efficacy in the treatment of many GIT disorders, mainly recurrent clostridium difficile infection, in addition to inflammatory bowel disease, hepatic encephalopathy, chronic constipation, and colorectal cancer with mild and self-limited adverse effects.\textsuperscript{16} Other extradigestive clinical implications for FMT such as diabetes and obesity are showing promising results for future application.\textsuperscript{17} Although it is a cost-effective and readily available treatment option,\textsuperscript{18} previously published clinical trials showed conflicting results in symptoms improvement in IBS patients and improving QOL.\textsuperscript{19}

There was a noticeable difference among the clinical trials in the outcome measurement, patient baseline characteristics, and the dose, preparation, and route of administration of FMT. So the aim of this meta-analysis is to compare the efficacy of FMT with placebo through pooling the improvement in the symptom severity score (SSS) and QOL. We would also assess the safety of the procedure and if there are any associated serious adverse effects. Our study also aims to provide a better quality of evidence from the previous meta-analyses by including only RCTs and excluding non-peer-reviewed reports.

2 | MATERIALS AND METHODS

The guidelines of the Cochrane handbook of systematic reviews were followed during the conduction of this review.\textsuperscript{20} In addition to the regulations of preferred reporting items of systematic reviews and meta-analysis (The PRISMA 2020 update).\textsuperscript{21,22}

2.1 | Search strategy

We used MeSH terms to form the following search strategy ("irritable bowel syndrome") OR ("irritable" AND "bowel" AND "syndrome") OR ("IBS") AND ("fecal microbiota transplantation") OR ("faecal microbiota transplant") OR ("faecal microbiota transplantation") OR ("faecal microorganism transplant") OR ("faecal" AND "microbiota" AND "transplant") OR ("fecal" AND "microbiota" AND "transplant") OR ("fMT") to search four databases: PubMed, SCOPUS (Title and abstract search for terms), Cochrane library, Web Of Science on February 2021 and updated our search in October 2021, for a further check, two authors performed a manual search by screening the references of the included studies.

2.2 | Study selection

We included randomized controlled trials comparing the fecal microbiota transplant in IBS patients diagnosed using either Rome III or IV criteria with autologous transfer or placebo group. The main outcome was the change from baseline using the IBS-SSS scale at different time points. Our PICO criteria were:

- **Population**: Patients with IBS.
- **Intervention**: Fecal microbiota transplant by any route of administration and any dosage.
- **Comparison**: Control group or autologous transfer.
- **Outcome**: Change in IBS symptoms severity and disease control, also the safety and side effects of the intervention.

We excluded case reports, conference abstracts, and single-arm trials. We have gone through two steps to select the eligible studies, (1) title and abstract screening and (2) full-text screening; authors were grouped into two groups and each group performed the screening and data collection separately. The leader author resolved the disputes and compared the results from the two groups. The first and second authors were primarily responsible for data analysis and writing.

2.3 | Data extraction

We extracted the data from the included studies in two Excel sheets, in the first one, two authors extracted baseline
characteristics of the eligible patients: age, BMI, sex, years since the diagnosis, type of IBS, and so forth, and the other contained outcomes measurement, we divided the main outcomes into (a) primary outcomes: Change from baseline in IBS symptom severity score at 1, 3–4 months, and at the time of last assessment (mean/standard deviation [SD]); total number of patients who achieved 50 or more points decrease in IBS-SSS; (b) secondary outcomes: QOL score (mean/SD); adverse events such as nausea, abdominal pain, diarrhea, constipation, and bloating. And after finishing the task every two authors revised the other two authors’ work; S. A. N. and Y. H. A. revised the entire work.

2.4 Risk of bias assessment

We used the Cochrane tool to assess the risk of bias in randomized trials (ROB 1), as described in Chapter 8.5. of the Cochrane book depending on the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias (missing protocol or funding issues would be considered as a source of risk), each item was graded as high risk, low risk, or unclear risk of bias.

2.5 Data analysis

We used the Review Manager Software version 5.3 to perform the meta-analysis; the continuous outcomes were measured as mean difference (MD) and SD, and the dichotomous outcomes as risk ratios (RR) with a 95% confidence interval (CI). In case of heterogeneity ($\chi^2 p < 0.1$), a random effect model was adopted, otherwise, a fixed-effect model was employed, and we used “take one out” method to resolve the heterogeneity, in general; the results were considered significant if the $p$-value was less than 0.05.

3 RESULTS

3.1 Literature search

The literature search retrieved 1490 citations after duplicates removal. After title and abstract screening, 94 articles were retrieved for further evaluation (full-text screening). Eight randomized trials were finally included. No other papers were found after the screening of the references of included trials and finally, 8 studies with 472 patients were included in data extraction (see PRISMA flow diagram; Figure 1).
| Study ID, Year       | Study Design                        | Study Site  | Sample Size | Diagnostic Criteria Used | Study Groups | Number of Patients | Mean age (SD)   |
|---------------------|-------------------------------------|-------------|-------------|--------------------------|--------------|--------------------|----------------|
| Holvoet et al., 2021 | Placebo-Controlled, double-blinded RCT | Belgium     | 62          | Rome III                | FMT          | 43                 | 40.8(5)        |
|                     |                                     |             |             |                          | Placebo      | 19                 | 38.25(11.25)   |
| Lahtinen et al., 2020 | Randomized clinical trial          | Finland     | 49          | Rome IV                 | FMT          | 23                 | 47.3(16.8)     |
|                     |                                     |             |             |                          | Placebo      | 26                 | 46.3(14.3)     |
| El-Salhy et al., 2020 | Placebo-Controlled, double-blinded RCT | Norway     | 163         | Rome III                | FMT          | 54                 | 39.2(12.4)     |
|                     |                                     |             |             |                          | FMT          | 55                 | 39.3(13.2)     |
|                     |                                     |             |             |                          | Placebo      | 55                 | 41.2(13.7)     |
| Johnsen et al., 2020 | Placebo-Controlled, double-blinded RCT | Norway     | 83          | Rome III                | FMT          | 55                 | 43.67(15.56)   |
|                     |                                     |             |             |                          | Placebo      | 28                 | 45.3(17.03)    |
| Halkjær et al., 2019 | Placebo-Controlled, double-blinded RCT | Denmark   | 51          | Rome III                | FMT          | 25                 | 37.28(12.48)   |
|                     |                                     |             |             |                          | Placebo      | 26                 | 35.54(10.58)   |
| Holster et al., 2019 | Randomized Controlled Trial         | Sweden      | 16          | Rome III                | FMT          | 8                  | 36.67(16.3)    |
|                     |                                     |             |             |                          | Placebo      | 8                  | 38.33(7.41)    |
| Aroniadis et al., 2019 | Placebo-Controlled, double-blinded RCT | USA       | 48          | Rome III                | FMT          | 25                 | 36(15.56)      |
|                     |                                     |             |             |                          | Placebo      | 23                 | 39.33(14.81)   |
| Johnsen et al., 2018 | Placebo-Controlled, double-blinded RCT | Norway     | 83          | Rome III                | FMT          | 55                 | 43.67(15.56)   |
|                     |                                     |             |             |                          | Placebo      | 28                 | 45.3(17.03)    |

| Study ID, Year       | Male n (%)  | Dose                                                                                     | Route of Administration | Mean Years with IBS | IBS Subtypes | Total Follow-up Time | Primary endpoint to define improvement                                                                 | Outcomes                                                                 |
|---------------------|-------------|-------------------------------------------------------------------------------------------|------------------------|---------------------|---------------|----------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Holvoet et al., 2021 | 13 (31%)    | Single 300 ml dose consisting of 30 gm freshly donated feces                            | Nasojejunal            | 10                  |               | 12 months            | Relief of general IBS symptoms and abdominal bloating at 12 weeks                                      | More patients in the active treatment group showed improvement in the general IBS symptoms than the placebo-treated group. |
|                     | 11 (59%)    | Single 300 ml dose consisting of 30 gm patients’ own feces                              |                        |                     |               |                      |                                                                                                       |                                                                          |
| Lahtinen et al., 2020 | 11 (48%)    | Single dose of 30 gm fecal suspension from a single universal donor                      | Gastroscope            |                     | IBS-D: 9, IBS-M: 3 | 13 months            | >> 50 point reduction in the IBS Symptom Severity Score                                                | There was no significant difference in the primary endpoint achievement between the treatment group and the placebo group. |
|                     | 9 (35%)     | Single dose of 30 gm fecal suspension from patients’ own stools                            |                        |                     | IBS-D: 16, IBS-M: 4 |                      |                                                                                                       |                                                                          |
| Study ID, Year     | Male n (%) | Dose                                                                 | Route of Administration | Mean Years with IBS | IBS Subtypes | Total Follow-up Time | Primary endpoint to define improvement | Outcomes                                                                                   |
|-------------------|------------|----------------------------------------------------------------------|-------------------------|---------------------|--------------|---------------------|------------------------------------------|-------------------------------------------------------------------------------------------|
| El-Salhy et al., 2020 | 14 (26%)   | Single dose of 30gm donor feces mixed with 40 ml sterile saline       | Gastroscope             | 17                  | IBS-C: 20 IBS-D: 22, IBS-M: 13 | 18 months | >= 50 point reduction in the IBS Symptom Severity Score at 12 weeks | More patients in the active treatment groups showed improvement in the IBS-SSS than the placebo group. In addition, patients treated with 60 g of FMT showed more improvement in the scores than patients treated with 30 g of FMT. |
|                   | 9 (16%)    | Single dose of 60gm donor feces mixed with 40 ml sterile saline       |                         | 17                  | IBS-C: 20 IBS-D: 20, IBS-M: 14 |           |                     |                                          |                                                                                           |
|                   | 8 (15%)    | Single dose of 30gm patients' own feces mixed with 40 ml sterile saline |                         | 17                  | IBS-C: 22 IBS-D: 21, IBS-M: 12 |           |                     |                                          |                                                                                           |
| Johnsen et al., 2020 | 19 (35%)   | Single dose of 50 - 80 g of fresh faces homogenized in 200 mL of isotonic saline and 50 mL of 85% glycerol | Colonoscope             | 11.33               | IBS-D: 31, IBS-M: 24 | 12 months |                     | - The effect on QoL is significant at six months, but not maintained at twelve months. - The effect on fatigue is significant at six, but not at three and twelve months. | FMT induced significant relief in quality of life and fatigue. |
|                   | 9 (32%)    | Single dose of 50 - 80 g of patients' own faces homogenized in 200 mL of isotonic saline and 50 mL of 85% glycerol |                         | 10.67               | IBS-D: 13, IBS-M: 15 |           |                     |                                          |                                                                                           |
| Halkjær et al., 2019 | 8 (32%)    | Single daily dose of 25 capsules containing 50 gm frozen fecal matter for 12 days | Oral                    | IBS-C: 7 IBS-D: 7, IBS-M: 11 | 6 months | >= 50 point reduction in the IBS Symptom Severity Score at 12 weeks | More patients in the placebo group showed improvement in the IBS-SSS than the patients in the FMT group. | There was no significant difference in the primary endpoint achievement between the active treatment group and the placebo group. |
|                   | 8 (30.8%)  | Single daily dose of 25 placebo capsules for 12 days                 |                         | IBS-C: 10 IBS-D: 8, IBS-M: 8 |           |                     |                                          |                                                                                           |
| Holster et al., 2019 | 5 (62.5%)  | Single dose of 150 ml FMT containing 30 g of freshly delivered feces mixed with sterile saline solution and 10% glycerol | Colonoscope             | unknown: 0, 1-5 yr: 4, 5 yr: 4 | IBS-C: 1 IBS-D: 5, IBS-M: 2 | 6 months | >= 30 point decrease in gastrointestinal symptom rating scale-IBS | There was no significant difference in the primary endpoint achievement between the active treatment group and the placebo group. |                                                                                           |
|                   | 3 (37.5%)  | Single dose of 150 ml FMT containing 30 g of patients' own feces mixed with sterile saline solution and 10% glycerol |                         | Unknown: 1, 1-5 yr: 3, 5 yr: 4 | IBS-C: 3 IBS-D: 4, IBS-M: 1 |           |                     |                                          |                                                                                           |
| Study ID, Year | Male n (%) | Dose | Route of Administration | Mean Years with IBS | IBS Subtypes | Total Follow-up Time | Primary endpoint to define improvement | Outcomes |
|---------------|------------|------|-------------------------|---------------------|-------------|---------------------|----------------------------------------|---------|
| Aroniadis et al., 2019<sup>16</sup> | 16 (64%) | Single daily dose of 25 capsules containing 12 gm frozen fecal matter for 3 days | Oral | 6.33 | IBS-D: 25 | 6 months | >= 50 point reduction in IBS Symptom Severity Score at 12 weeks | There was no significant difference in the primary endpoint achievement between the active treatment group and the placebo group. |
| | 14 (61%) | Single daily dose of 25 placebo capsules for 3 days | | 8.33 | IBD-D: 23 | | | |
| Johnsen et al., 2018<sup>27</sup> | 19 (35%) | Single dose of 50 - 80 g of fresh faces homogenized in 200 mL of isotonic saline and 50 mL of 85% glycerol | Colonoscope | 11.33 | IBS-D: 31, IBS-M: 24 | 12 months | >= 75 point reduction in the IBS Symptom Severity Score at 12 weeks | More patients in the active treatment group showed improvement in the IBS-SSS than the patients in the placebo group. |
| | 9 (32%) | Single dose of 50 - 80 g of patients’ own faces homogenized in 200 mL of isotonic saline and 50 mL of 85% glycerol | | 10.67 | IBS-D: 13, IBS-M: 15 | | | |

FMT: Fecal Microbiota transfer, IBS-C: Irritable bowel syndrome constipation type, IBS-D: Irritable bowel syndrome diarrhea type, IBS-M: Irritable bowel syndrome mixed type.

### 3.2 Characteristics of the included studies

Change from baseline (IBS-SSS) change from baseline after 3/4 months (IBS-SSS) the number of patients who achieved more than or equal to 50 points decrease (IBS-SSS) score. Change from baseline after 1 month (QOL score) outcomes were reported in 5, 3, 4, and 2 studies, respectively. Nausea, abdominal pain, bloating adverse events were reported in 5, 5, 3, 4, and 4 studies, respectively. The total number of patients included in the meta-analysis in the FMT group was 288 patients. Patients baseline data and studies are shown in Supporting Information: File 1.
(6) Change from the baseline after 1 month (QOL score).

The pooled effect showed that FMT intervention significantly improves QOL at 1 month compared to the control groups (MD = 7.044, [95% CI = 2.26 – 12.62], \( p = 0.005 \)). We observed no significant heterogeneity between the two studies (\( p = 0.85, I^2 = 0\% \)) (Figure 4).

(7) Number of respondents (Global improvement).

The pooled effect showed no statistically significant difference between the FMT and control groups in all routes together (RR = 1.84, [95% CI = 0.82 – 2.65], \( p = 0.19 \)) (Supporting Information: File 2, Figure 2).

We performed a subgroup analysis to test the effect of the type of route of administration on the number of respondents to treatment. The subgroup analysis was performed in oral, colonoscopy, nasojejunal, and gastroscope routes. The pooled
effect showed no statistically significant difference between the FMT and control groups in colonoscopy and nasojejunal routes (RR = 0.77, [95% CI = 0.54–1.10], p = 0.16) (RR= 2.12, [95% CI = 0.95–4.71], p = 0.06), respectively (Supporting Information: File 2, Figure 2). The pooled effect showed a statistically significant association between the FMT and increased number of respondents in oral and gastroscope routes (RR = 2.03, [95% CI = 1.25–3.31], p = 0.004) (RR= 3.49, [95% CI = 2.47–4.94], p < 0.00001), respectively (Supporting Information: File 2, Figure 2).

- Adverse events

(1) Nausea

The pooled results showed no statistically significant difference between the FMT and control groups (RR = 0.77, [95% CI = 0.54–1.10], p = 0.16). We observed no significant heterogeneity (p = 0.33, I² = 0%) (Figure 6).

(2) Abdominal pain/cramping/tenderness

The pooled results showed that FMT is associated with more abdominal pain and cramping compared to the control group.
We observed no significant heterogeneity (p = 0.28, I² = 21%) (Figure 6).

### Diarrhea

The pooled effect showed no statistically significant difference between the FMT and control groups (RR = 2.29, [95% CI = 0.55–9.50], p = 0.25) (Figure 5). We observed heterogeneity (p = 0.008, I² = 71%), so we did leave one out test by removing Aroniadis et al., and the heterogeneity was solved (p = 0.25, I² = 26%) and the results showed statistically significant difference between FMT and control groups (RR = 3.87, [95% CI = 1.29–11.59], p = 0.02).

### Constipation

The pooled results showed that FMT is associated with more constipation compared to the control groups (RR = 5.77, [95% CI = 1.63–20.42], p = 0.007). We observed no significant heterogeneity (p = 0.14, I² = 48%) (Figure 6).

### Bloating

The pooled effect showed no statistically significant difference between the FMT and control groups (RR = 1.24, [95% CI = 0.60–2.58], p = 0.56). We observed no significant heterogeneity (p = 0.26, I² = 25%) (Figure 6).

### DISCUSSION

The results of our meta-analysis showed that there is no statistically significant difference between the FMT group and the control group in the symptom severity score (IBS-SSS) at 1, 3–4 months, and the overall change at the end of the study. NO statistically significant difference was found in the number of patients who achieved more than or equal to 50 points decrease in IBS-SSS, and the number of respondents in the intervention group compared to the control group. The only outcome that shows a significant difference between the two groups is the QOL score, which indicates that (FMT) offers a better QOL for patients included in our study (MD = 9.32, 95% CI = 4.08–14.55, p = 0.0005). Based on the analysis of the adverse events, we found no statistically significant difference in nausea, diarrhea, and bloating. However, FMT was found to increase the risk of abdominal pain/cramping/tenderness, and constipation.

These results of the outcome (IBS-SSS) agree with two of the included studies, while contradicting two others, in which, both show a significant improvement in symptoms in both groups. The observed improvement in the placebo group was more obvious in Johnsen et al. Lahtinen et al. observed a transient effect for the intervention and they referred it to the different donors used in the study and the unchanged faulty dietary habits of the recipients. On the other hand, all individual studies showed improvement in (QOL score) except Halkjær et al. which showed more improvement in the placebo group. Two of our included studies assessed the long-term effect of FMT, and they both showed a decrease in the responders’ percentage after 1 year to 55% and 21%. This indicates that the beneficial effect of FMT decays over time.

Our results dispute with the results of the previous meta-analyses by Ianiro et al. and Xu et al. In the study by Xu et al., they reported that a single dose introduced by colonoscopy and the nasojejunal tube is more effective than multiple oral doses. We did a subgroup analysis on both methods and found no significant improvement in IBS symptoms in either of them (Supporting Information: File 2, Figure 1). Similarly, in the study by Ianiro et al., they showed a significant improvement in the use of colonoscopy and nasojejunal tube. Interestingly, they found that oral placebo capsules were more significant than oral FMT. This conflict in

| Study or Subgroup | FMT | Control | Weight | Risk Ratio | Risk Ratio |
|-------------------|-----|---------|--------|------------|------------|
|                   | Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Random, 95% CI |
| Aroniadis, 2019   | 11    | 22     | 14     | 23     | 25.2% | 0.39 [0.12, 1.29] |
| El-Salyh, 2020    | 9     | 109    | 13     | 55     | 25.6% | 3.53 [2.18, 5.72] |
| Halkjær, 2019     | 8     | 22     | 19     | 24     | 24.7% | 0.46 [0.25, 0.83] |
| Lahtinen, 2020    | 11    | 23     | 11     | 26     | 26.2% | 1.01 [0.61, 1.71] |
| Subtotal (95% CI) | 176   | 403    | 128    | 250    | 100.0% | 1.12 [0.44, 2.83] |

Total events 121 57
Heterogeneity: Tau² = 0.82, Chi² = 34.07, df = 3 (P < 0.0001), I² = 91%
Test for overall effect: Z = 0.23 (P = 0.82)

### FIGURE 5

Forest plots of number of patients who achieved more than or equal to 50 points decrease in (IBS-SSS) score and diarrhea

(RR = 3.73, [95% CI = 1.57–7.23], p = 0.002). We observed no significant heterogeneity (p = 0.28, I² = 21%) (Figure 6).
results is mainly due to the different assessment methods used. They used dichotomous data for response or no response to FMT, which is of lower significance than SSS because it does not specify the different degrees of patients’ responses. Xu et al. also included a study published as a conference abstract, which is of low quality of evidence and carries a higher risk of bias.

Also, we believe that our report provides better evidence compared to the recently published study by Wu et al. which showed conflicting results with ours. First, they performed an overall analysis of the adverse events related to FMT, which showed no significant increase compared to placebo, while we performed our analysis on each adverse effect separately and found a significant increase in abdominal pain and constipation in FMT compared to placebo. They combined the adverse events in one outcome, which is misleading because adverse events differ in degree of significance and severity. Second, after a subgroup analysis on the route of administration of FMT, they reported that colonoscopy was associated with a more improvement in the global symptoms of IBS compared to placebo, while the oral route was inferior to placebo. We used the IBS-SSS, which is a more reliable assessment score than the global symptoms score, in our subgroup analysis and found that the oral route is associated with more improvement compared to placebo, while colonoscopy was inferior to placebo. Third, we included more clinical trials, which further validates our results.
Based on the variation in the GIT bacterial flora of IBS patients from the normal population and the analysis of the specific bacteria incriminated in each subtype, several treatment modalities in addition to FMT were developed to target and modulate the bacterial flora of IBS patients. Probiotics are an effective treatment, which aims at restoring the natural balance of GIT flora by increasing certain species of beneficial bacteria. Several types of bacteria were used as probiotics. Bacillus Coagulans MTCC 5856 is a very effective bacterial strain in reducing bloating and abdominal pain in diarrheal dominant IBS patients. It outstands other strains by its great durability for heat and acidic nature in the GIT due to its spore-forming nature, thus, it can have a longer duration of action. Future therapies for modulating GIT flora are now under development. A new technique using bacteriophages to target specific intestinal bacteria is now approved by FDA for further research.

Another promising therapy is the stem cell-based gut-on-a-chip. It creates a microenvironment for testing potential therapies and customizing them for each patient. Using antibiotics that are poorly absorbed from GIT like rifaximin and neomycin is now used more widely, but its main flaw is the lack of specificity as it may affect the harmless flora as well. Now, precision antimicrobial peptides called selectively targeted antimicrobial peptides were developed to target certain species without affecting the normal flora. This therapy was only used in dental caries, but in the future, it can be effective in IBS as well. Another similar technique is using the contractile nanotubes produced by certain bacteria that can attach to certain receptors on the cell wall of other bacteria and kill them. We can target certain pathogenic bacteria by modulating those contractile tubes to make them attach to the surface receptor of the pathogenic bacteria.

Diet is another important modifiable element in the pathogenesis of IBS. The two main proven dietary plans are eating low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) and gluten-free food. FODMAPs are short-chain carbohydrates that are poorly absorbed from the intestinal lumen. They have highly osmotic power, so they increase bloating and abdominal pain. They are also easily fermentable by intestinal flora with gas production which increases the feeling of bloating. A low FODMAP diet was shown to reduce IBS symptoms by 68% and offers a better QOL. On the other hand, gluten induces IBS symptoms without patients actually having celiac disease. This condition is called "non-celiac gluten sensitivity (NCGS)." Gluten-free diet is mainly effective in the diarrheal subtype where it is shown to reduce stool frequency in patients who are HLA-DQ2/8-positive. The mechanism is still unclear but it may be due to a genetically determined immune response.

For better symptom improvement in IBS patients, therapeutic measures and diet modification should be part of a more comprehensive management plan. The three main pillars for management are medications, dietary plans, and behavioral therapy. There is a reciprocal relationship between brain and gut mediated by hormones, CNS, and PNS. Chronic Stress, fear of symptoms, and lack of control of disease exacerbate the patient’s symptoms and decrease their QOL. Therefore, different behavioral therapies are now used and proved great efficacy in decreasing patients' symptoms and increasing their QOL such as gastrointestinal-focused cognitive behavioral therapy and gut-directed hypnotherapy. This requires a multidisciplinary team of gastroenterologists, dietitians, gut-focused hypnotherapists, psychiatrists, and cognitive-behavioral physiotherapists. Telephone and web-based cognitive behavioral therapy are showing even better efficacy than standard treatment but are much more cost-effective, yet long-term efficacy is not well established.

Three studies were limited by the small sample size of the patients included in both groups. Four other studies did not specify the type of the IBS major symptoms and this heterogeneity may affect the patients’ response variably. Mixed donors for FMT, who have different microbiota compositions is another limitation noticed in three other studies.

The main strength points of our study are as follows: first, we are the first meta-analysis to plot the degree of improvement in symptoms by using symptom severity score as a scaling system, unlike the previous meta-analyses which plotted the improvement of patients as dichotomous data that does not show the degree of improvement in these patients. Second, we included RCT only and unlike the previous meta-analysis, we did not include single-arm trials and conference abstract, which increases the impact of our study. Third, we did a precise screening for all databases present and included all eligible studies. We also assessed the risk of bias for all included studies and it was generally low, which increases the quality of evidence in our study. However, our study was limited by the significant heterogeneity found in most of the results outcomes and that heterogeneity mostly could not be resolved by the normal statistical ways, which implies that our results are not biologically plausible. Our systematic review was not registered. However, we described our methodology precisely and provided a PRISMA checklist and justified the authors’ assessment of the risk of bias. Moreover, we could not analyze some of the outcomes because they were not assessed in all the included trials.

In conclusion, FMT is not an effective treatment for IBS symptoms whether it is administered orally, by colonoscopy, gastroscopy, or through a nasojejunal tube. Although it may show a transient effect in some patients, this effect wears off drastically over time, and even after repeated administration, it does not show the initial effect, which suggests that it is only a placebo effect. Future studies should be directed toward probiotics and newer technologies in modulating GIT bacterial composition, as well as diet modification. Integrated management for IBS patients is now strongly advised as it addresses all pathological aspects of the disease.

AUTHOR CONTRIBUTIONS
Yonna Ali Abdelghafar: Conceptualization; data curation; writing – original draft; writing – review & editing. Yossef Hassan AbdelQadir: Conceptualization; formal analysis; methodology; software; supervision; writing – review & editing. Karam R. Motawea: Formal analysis; visualization. Sara Amr Nasr: Conceptualization; data curation; validation. Hoda Aly Mohamed Omran: Data curation; validation. Mohamed...
Mohamed Belal: Data curation; validation. Mohamed Mahdy Elhashash: Data curation; validation. Ahmed Alaa AbdelAzim: Formal analysis; visualization. Jaffer Shah: Formal analysis; visualization.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

TRANSPARENCY STATEMENT
The lead author Jaffer Shah affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable because no new data was generated except for the data presented in the results section of the manuscript.

ORCID
Jaffer Shah http://orcid.org/0000-0002-8961-218X

REFERENCES
1. Mizuno S, Masaoka T, Naganuma M, et al. Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome. Digestion. 2017;96(1):29-38. doi:10.1159/000471919
2. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859-867. doi:10.1136/GUTJNL-2019-319630
3. Patel N, Shackelford KS. Irritable Bowel Syndrome. StatPearls; 2021. Accessed November 30, 2021. https://www.ncbi.nlm.nih.gov/books/NBK534810/
4. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159-176. doi:10.1136/gutjnl-2012-302167
5. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-917. doi:10.1016/S2468-1253(20)30217-X
6. Sperber AD. Epidemiology and burden of irritable bowel syndrome: an international perspective. Gastroenterol Clin North Am. 2021;50(3):489-503. doi:10.1016/j.gtc.2021.04.001
7. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. J Am Med Assoc. 2015;313(9):949-958. doi:10.1001/jama.2015.0954
8. Aroniadis OC, Brandt LJ, Oneto C, et al. Faecal microbiota transplantation for diarrhea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019;4(9):675-685. doi:10.1016/S2468-1253(19)30198-0
9. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99-114. doi:10.1053/j.gastro.2020.04.014
10. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473-486. doi:10.1038/s41575-020-0286-8
11. Simpson CA, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. J Affect Disord. 2020;266:429-446. doi:10.1016/j.jad.2020.01.124
12. Tang H-Y, Jiang A-J, Wang X-Y, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187. doi:10.21037/ATM-21-2779
13. Chey W, Menees S. The gut microbiome and irritable bowel syndrome version 1; referees: 3 approved. F1000Research. 2018;7:1-10. doi:10.26888/F1000research.14592.1
14. Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci. 2020;36(3):160-170. doi:10.1002/kjm2.12154
15. Goldenberg SD, Merrick B. The role of faecal microbiota transplantation: looking beyond clostridioides difficile infection. Ther Adv Infect Dis. 2021;8:1-16. doi:10.1177/204993612091526
16. Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019;70:335-351. doi:10.1146/ANNUREV-MED-111717-122956
17. Filip M, Tzaneva V, Dumitrascu DL. Fecal transplantation: digestive and extradigestive clinical applications. Cluj Med. 2018;9(13):259-265. doi:10.15386/CJMED-946
18. El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2018;12(5):439-445. doi:10.1080/17474124.2018.1447380
19. Hallbjörn Sl, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115. doi:10.1136/GUTJNL-2018-316434
20. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration®.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7716):332-336. doi:10.1136/bmj.b2535
22. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/BMJ.N71
23. Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome: results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145-157. doi:10.1053/J.GASTRO.2020.07.013
24. Lahtinen P, Jalanka J, Hartikainen A, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321-1331. doi:10.1111//apt.15740
25. Johnsen PH, Hilpüsch F, Valle PC, Goll R. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-contipated irritable bowel: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021;160(1):145-157. doi:10.1053/J.GASTRO.2020.07.013
26. Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study. Clin Transl Gastroenterol. 2019;10(4):e00034. doi:10.14398/CTG.0000000000000034
27. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate to severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi:10.1016/S2468-1253(17)30338-2
28. Mazzawi T, Hausken T, How JR, et al. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels. Scand J Gastroenterol. 2019;54(6):690-699. doi:10.1080/003655521.2019.1624815

29. Xu D, Chen VL, Steiner CA, et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2021;116(7):1043-1050. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257434/

30. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240-248. doi:10.1111/apt.15330

31. Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2022;12:179. doi:10.3389/FICMB.2022.827395/BIBTEX

32. Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota composition and short-chain fatty acid levels associated with diarrhea-predominant irritable bowel syndrome. J Gastroenterol. 2019;54(5):903-910. doi:10.1007/S00394-019-02868-6

33. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072-3084. doi:10.3748/WJG.v21.i10.3072

34. Majeeed M, Nagabhushanam K, Natarajan S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15(1):21. doi:10.1186/s12973-016-0140-6

35. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-124. doi:10.3810/PGM.2009.03.1984

36. Workman MJ, Gleeson JP, Troisi EJ, et al. Enhanced utilization of induced pluripotent stem cell-derived human intestinal organoids using microengineered chips. Cell Mol Gastroenterol Hepatol. 2017;5(4):669-677. doi:10.1016/J.CMGH.2017.12.008

37. Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(1):1278-1285. doi:10.1007/s10620-014-3157-8

38. Eckert R, He J, Yarbrough DK, Qi F, Anderson MH, Shi W. Targeted killing of Streptococcus mutans by a pheomone-guided "smart" antimicrobial peptide. Antimicrob Agents Chemother. 2006;50(11):3651-3657. doi:10.1128/AAC.00622-06

39. Ge P, Scott D, Leiman PG, Yu X, Miller JF, Zhou ZH. Atomic structures of a bactericidal contractile nanotube in its pre- and postcontraction states. Nat Struct Mol Biol. 2015;22(5):377-382. doi:10.1038/nsmb.2995

40. Dionne J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol. 2018;113(9):1290-1300. doi:10.1038/s41395-018-0195-4

41. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016;55(3):897-906. doi:10.1007/S00394-015-0922-1

42. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510-1518. doi:10.3945/JN.112.159285

43. Marchioni Beery RM, Birk JW. Wheat-related disorders reviewed: making a grain of sense. Expert Rev Gastroenterol Hepatol. 2015;9(6):851-864. doi:10.1586/17474124.2015.1032252

44. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013;144(5):903-911. doi:10.1053/J.GASTRO.2013.01.049

45. Chery WD, Keefer L, Whelan K, Gibson PR. Behavioral and diet therapies in integrated care for patients with irritable bowel syndrome. Gastroenterology. 2021;160(1):47-62. doi:10.1053/J.GASTRO.2020.06.099

46. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61(9):1284-1290. doi:10.1136/GUTJNL-2011-300474

47. Laird KT, Tanner-Smith EE, Russell AC, Hollon SD, Walker LS. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(7):937-947. doi:10.1016/J.CGH.2015.11.020

48. Basnayake C, Kamm MA, Stanley A, et al. Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5(10):890-899. doi:10.1016/S2468-1253(20)30226-5

49. Everitt H, Landau S, Little P, et al. Therapist telephone guided CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT. Health Technol Assess. 2019;23(17):1-154. doi:10.3310/HTA23170

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Abdelghafar YA, AbdelQadir YH, Motawea KR, et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: an update based on meta-analysis of randomized control trials. Health Sci Rep. 2022;5:e814. doi:10.1002/hsr2.814